Sarcomatrix

Sarcomatrix, Inc. is a biopharmaceutical company pioneering novel therapeutics that leverage our understanding of muscle biology and tissue regeneration to develop therapies that have potential for broad clinical applicability across multiple disease areas of high unmet need. Our current focus in muscular dystrophy. Muscular dystrophy, a rare disease without a cure, reduces a patients average life expectancy to 26 years. Our goal is to more than double their life expectancy. Our IP protected vast portfolio of small molecules α7β1 integrin activators and proteins, used as single agents or in combination with cell/gene therapy, may ultimately cure muscular dystrophy.